TrialsgrambetaRCTs are beautiful

POISE-3

2022

PeriOperative ISchemic Evaluation-3 trial

In 9,535 patients undergoing non-cardiac surgery at risk of bleeding and cardiovascular events, intravenous tranexamic acid reduced life-threatening, major or critical-organ bleeding at 30 days, but non-inferiority for the cardiovascular safety composite was not established compared with placebo.

Result

Efficacy: Composite bleeding outcome at 30 days; safety composite of myocardial injury, stroke, arterial thrombosis or venous thromboembolismHR 0.76 (95% CI 0.67-0.87) · P < 0.001

Safety: Cardiovascular safety compositeHR 1.02 (95% CI 0.92-1.14)

Below 1 favours intravenous tranexamic acid, above 1 favours placebo.

Event rates Intravenous tranexamic acid 9.1% vs placebo 11.7% (composite bleeding outcome at 30 days; safety composite of myocardial injury, stroke, arterial thrombosis or venous thromboembolism)

Also reported: Missing the prespecified non-inferiority margin.

Original publication
Subtopic
Antifibrinolytic therapy
Design
Partial factorial, double-blind, placebo-controlled RCT
Relevance
Important: one of several pillars.
Source
Devereaux PJ, Marcucci M, Painter TW, et al. N Engl J Med. 2022;386(21):1986-1997.doi 10.1056/NEJMoa2201171

Discussion & critique

Non-inferiority for cardiovascular safety formally failed, so a small thrombotic hazard cannot be excluded, and the separately reported blood-pressure-management comparison was neutral. It is by far the largest antifibrinolytic trial in non-cardiac surgery and establishes tranexamic acid as a bleeding-reduction strategy with an explicit thrombotic caveat.

Discussed in podcasts